Price
Target price
€1.26
€1.26
-0.470%
-0.006
-0.470%
€5.10
22.04.24 / Frankfurt
WKN: A2AFXS / Symbol: CRVS / Name: Corvus / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Corvus Pharmaceuticals Inc Stock
Corvus Pharmaceuticals Inc shows a slight decrease today, losing -€0.006 (-0.470%) compared to yesterday.
Our community is currently high on Corvus Pharmaceuticals Inc with 4 Buy predictions and 1 Sell predictions.
With a target price of 5 € there is potential for a 297.46% increase which would mean more than doubling the current price of 1.26 € for Corvus Pharmaceuticals Inc.
Our community identified positive and negative aspects for Corvus Pharmaceuticals Inc stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Corvus Pharmaceuticals Inc stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Corvus Pharmaceuticals Inc in the next few years
Pros
?
B****
?
S********** s********
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Corvus Pharmaceuticals Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Corvus Pharmaceuticals Inc | -0.470% | -8.406% | -22.927% | 34.468% | -16.842% | -46.441% | -62.856% |
| Ardelyx Inc. | 0.130% | -4.466% | -13.831% | 35.956% | 5.848% | -10.686% | - |
| Salarius Pharmaceuticals Inc. | 0.950% | -2.778% | -19.231% | -68.421% | -24.324% | -98.250% | -99.994% |
| Brainstorm Cell | -4.690% | -0.586% | 0.792% | -81.287% | 119.397% | -80.271% | - |
Comments
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Show more
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $8.00 to $7.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $4.00 price target on the stock.
Show more
Ratings data for CRVS provided by MarketBeat